Upfront Cytoreductive Nephrectomy for Metastatic RCC Treated With Immune Checkpoint Inhibitors or Targeted Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium
Eur Urol 2022 Oct 19;[EPub Ahead of Print], Z Bakouny, T El Zarif, S Dudani, J Connor Wells, CL Gan, F Donskov, J Shapiro, ID Davis, F Parnis, P Ravi, JA Steinharter, N Agarwal, A Alva, L Wood, A Kapoor, JM Ruiz Morales, C Kollmannsberger, B Beuselinck, W Xie, DYC Heng, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.